Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017
Summary
GlobalData's clinical trial report, “Age Related Macular Degeneration Global Clinical Trials Review, H1, 2017" provides an overview of Age Related Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Age Related Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Age Related Macular Degeneration Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Age Related Macular Degeneration 33
Mar 09, 2017: Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of Orally Administered Vorolanib for Wet Age-related Macular Degeneration 33
Mar 08, 2017: Opthea Completes FDA Meeting to Inform OPT-302 wet AMD Clinical Program 33
Feb 27, 2017: Xbrane Biopharma Reports Positive in-vitro Biosimilarity Data on Xlucane 33
Feb 09, 2017: Iconic Therapeutics to Present Phase 2a EMERGE Trial Results at Miami Meeting 34
Clinical Trial Profile Snapshots 35
Appendix 486
Abbreviations 486
Definitions 486
Research Methodology 487
Secondary Research 487
About GlobalData 488
Contact Us 488
Source 489
List Of Tables
List of Tables
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2017* 6
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Age Related Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Age Related Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Age Related Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Age Related Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
Age Related Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15
Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 19
Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Age Related Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
Lisst Of Figures
List of Figures
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Age Related Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Age Related Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Age Related Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Age Related Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
Age Related Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15
Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Age Related Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Age Related Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 18
Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Age Related Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Age Related Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Age Related Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Age Related Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 487
